Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055630 | 0.92 | SMN1; SMN2 (0.75) | SMN1; SMN2MAPTPKMMEN1KMT2A | |
| SCHEMBL8055574 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTPKMMEN1KMT2A | |
| SCHEMBL6365491 | 0.88 | SMN1; SMN2 (0.82) | SMN1; SMN2MAPTPKMKDM4EMEN1 | |
| SCHEMBL8065340 | 0.80 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPTPKMMEN1KMT2A | |
| SCHEMBL8056219 | 0.79 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL1452 | 0.78 | SMN1; SMN2 (1.00) | SMN1; SMN2MAPTPKMMEN1KMT2A | |
| SCHEMBL6442004 | 0.77 | SMN1; SMN2 (0.78) | SMN1; SMN2MAPTPKMMEN1KMT2A | |
| SCHEMBL13743000 | 0.77 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPTPKMMEN1KMT2A | |
| SCHEMBL6362154 | 0.76 | SMN1; SMN2 (0.63) | SMN1; SMN2MAPTPKMMEN1KMT2A | |
| SCHEMBL7847021 | 0.74 | SMN1; SMN2 (0.90) | SMN1; SMN2MAPTPKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194529-A1 | HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194529-A1 | HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS | PDE5A, PDE7A, PDE3A | SMN1; SMN2 1886/4885MAPT 4520/4885PKM 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.